What is the half-life of PTD-DBM?

PTD-DBM has a half-life of ~2-4 hours (estimated from preclinical data), which is why it's typically administered Once daily (topical application to scalp) for optimal therapeutic effect.

How do I reconstitute PTD-DBM?

Add bacteriostatic water to the peptide vial slowly down the side. Typical reconstitution uses 2-3ml of water for a 5mg vial. Gently swirl, do not shake.

Healing & Recovery

Preclinical

PTD-DBM

Also known as: PTD-DBM Peptide, Wnt Activator Peptide

Overview

Key Facts

Primary Goal: A cell-permeable peptide designed to activate the Wnt/beta-catenin signaling pathway by disrupting the CXXC5-Dishevelled interaction

A cell-permeable peptide designed to activate the Wnt/beta-catenin signaling pathway by disrupting the CXXC5-Dishevelled interaction. This pathway is critical for hair follicle neogenesis and cycling. PTD-DBM has shown remarkable results in preclinical models, stimulating new hair follicle formation from stem cells — a mechanism distinct from existing hair loss treatments that merely preserve existing follicles. Half-Life ~2-4 hours (estimated from preclinical data) Typical Dose 0.5–2 mg Frequency Once daily (topical application to scalp) Cycle Length 12-24 weeks for initial hair growth assessment

Dosing Information

Half-Life

~2-4 hours (estimated from preclinical data)

Typical Dose

0.5–2 mg

Frequency

Once daily (topical application to scalp)

Cycle Length

12-24 weeks for initial hair growth assessment

Administration Routes:

subcutaneoustopical

Storage & Reconstitution

Unreconstituted (Powder)

Temperature2–8°C (36–46°F) or -20°C (-4°F) for long-term

DurationUp to 3 months

Reconstituted (Mixed)

Temperature2–8°C (36–46°F)

Duration2-4 weeks

Research Summary

Preclinical

Published in 2017 by researchers at Yonsei University (South Korea) in the Journal of Investigative Dermatology, PTD-DBM demonstrated new hair follicle formation in mice — a result not achieved by any currently approved hair loss treatment. The study showed that topical application to wound sites produced fully functional hair follicles from stem cells. The mechanism targets CXXC5, a negative regulator of Wnt signaling that is overexpressed in balding scalp. While extremely promising, the peptide remains in preclinical development with human trials pending.